Comparison of fluorescent SSCP and denaturing HPLC analysis with direct sequencing for mutation screening in hypertrophic cardiomyopathy

J Mogensen, A Bahl, T Kubo, N Elanko, R Taylor, W J McKenna

The recent achievement of the human genome project has led to the identification of many disease genes in common hereditary conditions, in which patients and their relatives would benefit from genetic diagnosis. This has increased the need for simple, sensitive, and cost effective methods of mutation analysis. However, the "gold standard" of mutation analysis, direct sequencing, is still an expensive and labour intensive method for investigation of large genes, multi-allelic diseases, and large numbers of patients. Today the most frequently used methods for prescreening disease genes for mutations are single strand conformation polymorphism analysis (SSCP) and denaturing high performance liquid chromatography (DHPLC). Both methods accelerate mutation analysis (SSCP) and denaturing high performance liquid chromatography (DHPLC). Both methods accelerate mutation analysis, direct sequencing to a few abnormal polymerase chain reaction (PCR) products identified in the prescreening procedure.

The technique of SSCP analysis is based on the principle that changes in nucleic acid composition affect the conformation of single stranded DNA and thereby the mobility of the fragment when it is subjected to electrophoresis under non-denaturing conditions. Abnormal conformers identified in the prescreening procedure are subsequently investigated for the presence of sequence variants by direct sequencing. The technique was initially developed for manual gel electrophoresis in which the mobility of amplified PCR products was visualised by incorporation of radiolabelled nucleotides or by silver staining after electrophoresis. Recently, SSCP has been developed for automated capillary electrophoresis (CE) using buffered polymer solution as the sieving matrix for electrophoretic separation and fluorescence as the method of detection.

Fluorescent capillary electrophoresis SSCP (F-SSCP) has the advantage of limited "post-PCR" handling of samples, which are loaded and analysed automatically with the possibility of a high throughput. Also, the requirements for reagent and sample volumes are small. Previous studies have reported a high sensitivity and specificity of F-SSCP. However, the primary method of identifying mutations used to investigate the efficacy of mutation detection by F-SSCP is unclear in several reports. Some reports investigated the ability of F-SSCP to identify mutations initially disclosed by manual SSCP. Only a few of the previously reported test mutations were identified by direct sequencing or introduced in specific test DNA by site directed mutagenesis.

The technique of DHPLC has been developed more recently and relies on different retention times of homoduplex and heteroduplex DNA on ion pair reverse phase chromatography. Partial heat denaturation of samples decreases the retention time of mismatched DNA fragments compared with their intact double stranded counterparts. The method has similar advantages to F-SSCP. That is, automation, no "post-PCR" handling of samples, high throughput, and low cost, not least because PCR products are amplified with unlabelled primers. Several studies have reported high sensitivity and specificity when compared to mutations identified by various SSCP analyses and direct sequencing.

This study investigated the suitability of F-SSCP and DHPLC for detection of sequence variants in five disease genes associated with the phenotypic expression of the most common hereditary heart condition known as hypertrophic cardiomyopathy (HCM). The disease is characterised by unexplained thickening of the heart muscle and predominantly inherited as an autosomal dominant trait with a prevalence of about 1:500 in a young adult population. Initially, the five genes were subjected to direct sequencing in 100 patients and 78 different sequence variants were identified. Subsequently, F-SSCP analysis was developed for a 16 capillary electrophoresis machine (ABI Prism 3100 genetic analyser, Applied Biosystems) and the ability to detect abnormal conformers of sequence variants identified by direct sequencing was evaluated. Similarly, the ability of DHPLC (Wave 3500HT DNA fragment analysis system, Transgenomic) to detect the same sequence variants was investigated.

Key points

- The "gold standard" for mutation analysis, direct sequencing, is expensive and labour intensive for high throughput mutation screening, emphasising the need for alternative simple, sensitive, and cost effective methods for mutation analysis.
- We developed F-SSCP analysis for a 16 capillary electrophoresis machine and compared sensitivity, specificity, and reproducibility with DHPLC analysis. All 78 sequence variants (56 heterozygous, 22 homozygous) investigated by F-SSCP and DHPLC were initially identified by direct sequencing.
- The sensitivity of F-SSCP and DHPLC was 95% and 100% respectively, and the specificity was 97% for F-SSCP and 100% for DHPLC. Both methods were highly reproducible.
- We conclude that both F-SSCP and DHPLC analysis are valuable tools for high throughput mutation screening with high sensitivity and specificity. Also, both methods require minimal "post-PCR" handling of samples, are easily optimised, and have low running costs.

Abbreviations: CE, capillary electrophoresis; DHPLC, denaturing high performance liquid chromatography; F-SSCP, fluorescent capillary electrophoresis SSCP; GLA, α-galactosidase; HCM, hypertrophic cardiomyopathy; PCR, polymerase chain reaction; PRKAG2, AMP activated protein kinase; RFU, relative fluorescence units; SSCP, single strand conformation polymorphism; TNNI3, troponin I; TNNT2, troponin T; TPM1, tropomyosin
MATERIALS AND METHODS

Blood samples were obtained from patients with hypertrophic cardiomyopathy in accordance with guidelines from the local ethics committee. Informed consent was obtained from all participants.

The protein encoding exons of the following genes, troponin T (TNNT2), troponin I (TNNI3), α-tropomyosin (TPM1), AMP activated protein kinase (PRKAG2), and α-galactosidase (GLA), were amplified using intronic primers designed according to the genomic sequences of the genes. One hundred samples were sequenced in all exons (52 in total) of each of these genes. Primer sequences, PCR conditions for amplification of each of the genes, and the manual used for direct sequencing are available at our website (http://www.sghms.ac.uk/depts/cardiology/groups/Mogensen/data).

Fluorescent SSCP analysis of heterozygous sequence variants

The PCR product (1 µl) was mixed with deionised formamide (10 µl), NaOH (0.5 µl of a 0.3 M NaOH solution), and size standard (0.75 µl, ROX 500, Applied Biosystems). The sample was denatured at 95°C for five minutes and cooled on ice before loading. Capillary electrophoresis was performed on an ABI Prism 3100 genetic analyser (Applied Biosystems) through 16 capillaries with a length to detection of 36 cm using Genescan polymer (5%) with added glycerol (5%) and 1 × EDTA buffer under non-denaturing conditions. Electrophoresis was performed at three different temperatures (18°C, 25°C, 35°C) at varying injection times and voltages for 35–52 minutes to optimise the final analysis.

The mobility of F-SSCP fragments was measured relative to ROX size standard by use of Genescan software (Applied Biosystems). Subsequent analysis of fragments was performed with Genotyper software, version 3.7 (Applied Biosystems). A fragment was considered abnormal when shape or mobility was out of range of control fragments.

Fluorescent SSCP analysis of homozygous sequence variants

Analysis of homozygous sequence variants was essentially the same as for heterozygous variants. Fragments of control and test samples were analysed in two separate capillary electrophoreses. The concentration of each fragment was estimated as the peak height in relative fluorescent units (RFU) by use of Genotyper software. Subsequently, the control and test sample were mixed in equal concentration and reanalysed. A fragment was considered abnormal when shape or mobility was out of the range of control fragments.

DHPLC analysis of heterozygous sequence variants

Heteroduplex analysis was performed using a wave DNA fragment analysing system 3300HT (Transgenomic) in accordance with the manual of the manufacturer (details available on http://www.sghms.ac.uk/depts/cardiology/groups/Mogensen/data). Melting profiles for each DNA fragment were generated with Wavemaker 4.1.40 software (Transgenomic). Any peak falling below 1 mV was reinjected in a larger volume.

DHPLC analysis of homozygous sequence variation

Analysis of homozygous sequence variants was essentially the same as for heterozygous variants. Fragments of control and test samples were analysed in two separate analyses. The concentration of each fragment was estimated as the peak height in mV by use of Wavemaker software. Subsequently, control and test samples were mixed in equal concentration and reanalysed. A fragment was considered abnormal when shape or width of the peak was different from that of the wild type control.

Study design

A total of 23 different PCR fragments were analysed by F-SSCP and DHPLC, representing the exons of genes that contained 78 sequence variants initially identified by direct

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Standard electrophoresis settings for optimisation of fluorescent SSCP at three temperatures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>18°C</strong></td>
<td><strong>25°C</strong></td>
</tr>
<tr>
<td>IV IT</td>
<td>Distribution of optimal conformers</td>
</tr>
<tr>
<td>4 10 12</td>
<td>3 8</td>
</tr>
<tr>
<td>6 15 9</td>
<td>5 15</td>
</tr>
<tr>
<td>7 10 13</td>
<td>6 15</td>
</tr>
<tr>
<td>7 18 5</td>
<td>7 18</td>
</tr>
<tr>
<td>Total 39</td>
<td>Total 39</td>
</tr>
</tbody>
</table>

The distribution of optimal conformers of different PCR products is shown at various injection voltages (IV) and injection times (IT). PCR products ranged in size from 190–468 bp.
RESULTS

Direct sequencing

Samples of DNA from 100 patients with HCM were subjected to direct sequencing in five genes (52 exons) previously reported to be associated with the phenotypic expression of HCM. A total of 78 sequence variants were identified, of which 56 were heterozygous and 22 were homozygous (results are available on our website http://www.sghms.ac.uk/depts/cardiology/groups/Mogensen/data). Twenty-nine of the 56 heterozygous sequence variants were thought to be “disease causing” mutations and the remaining 27 were polymorphisms. Most sequence variants were single base substitutions (72/78, 92%), whereas only a few were insertions/deletions in the range of 1–5 base pairs (6/78, 8%).

Fluorescent SSCP for detection of heterozygous sequence variants

Initial optimisations were aimed at defining a set of conditions for F-SSCP by which the resolution of PCR products was suitable for analysis. The resolution is influenced by the amount of PCR product passing through the capillaries, which can be regulated by using different injection times (IT) and injection voltages (IV). The impact of 26 different IT/IV settings on the resolution of 15 different PCR products at three temperatures (IV) was determined by using forward and reverse primers labelled with the fluorescent dyes FAM and HEX, respectively. Optimal electrophoresis conditions for each of the different exons was determined with the IT/IV settings in table 1. The PCR products were subjected to capillary electrophoresis at three different temperatures and diagrams of representative conformers are shown in fig 2. Fifty-three of 56 (95%) heterozygous sequence variants were detected as abnormal conformers by F-SSCP (results available at http://www.sghms.ac.uk/depts/cardiology/groups/Mogensen/data). One “disease causing” mutation out of 29 was not detected by F-SSCP implying a mutation specific sensitivity of 97%.

It was apparent that use of two temperatures for F-SSCP analysis only (18°C, 35°C) achieved the same sensitivity as the use of all three temperatures tested (table 2). The run to run variability of F-SSCP was investigated by repeated electrophoresis (four times) of eight different PCR products at three temperatures. No significant change in fragment mobility was detected implying a high reproducibility of F-SSCP (data not shown). The specificity of F-SSCP was 97% after analysis of 966 PCR products of which 29 were identified as abnormal but turned out to be a wild type sequence on direct sequencing.

Previous investigations using manual SSCP electrophoresis have reported reduced mutation detection rates in PCR products above 300 bp. In the current study there was no difference when comparing detection rates of abnormal conformers of PCR products ranging from 100–300 bp and 301–500 bp (results available at http://www.sghms.ac.uk/depts/cardiology/groups/Mogensen/data). These results were in accordance with previous findings that F-SSCP can detect sequence variants in PCR products of up to 1200 bp.

Fluorescent SSCP for detection of homozygous sequence variants

Direct sequencing identified a total of 22 homozygous sequence variants (results available at http://www.sghms.ac.uk/depts/cardiology/groups/Mogensen/data). When subjected to F-SSCP without mixing the test and wild type control samples it was only possible to detect 15 of the 22 variants (70%). However, on mixing of the test and wild type sample in equal concentration it was possible to detect all homozygous sequence variants by F-SSCP analysis at three different temperatures (fig 3). Both test and wild type sequences were amplified with FAM labelled forward primers and HEX labelled reverse primers. In an attempt to enhance the separation of wild type and homozygous sequence variation, a primer set labelled “opposite” with HEX labelled forward and FAM labelled reverse primer was made. However, two complete separate peaks of FAM and HEX occurred after F-SSCP analysis of the same wild type PCR product when amplified with FAM forward primer and HEX forward primer.

<table>
<thead>
<tr>
<th>Table 2 Distribution of heterozygous sequence variations identified by fluorescent SSCP as a function of different analysis temperatures</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PCR products (No)</strong></td>
</tr>
<tr>
<td>23</td>
</tr>
</tbody>
</table>

www.jmedgenet.com
respectively. This indicated a different migration time for the dyes FAM and HEX and made it impossible to use for separation of wild type and homozygous sequence variations (data not shown).

**DHPLC for detection of heterozygous sequence variants**

In our experience analysis of PCR fragments by DHPLC analysis gives optimal resolution and reproducibility when the peak height of the eluted PCR product is above 1 mV. The identification rate of false positive PCR products ranged from 10%–20% when peaks were below 1 mV and therefore these fragments were reanalysed after reinjection of a larger sample volume. When necessary, the percentage of buffer B was optimised to obtain an elution time of PCR fragments of about two minutes, well away from the initial injection spike (figs 4 and 5). All test mutations were identified by analysis at one oven temperature.

All 56 heterozygous sequence variants were identified by DHPLC (results available at http://www.sghms.ac.uk/depts/cardiology/groups/Mogensen/data). The specificity of DHPLC after analysis of 384 PCR fragments was 100%.

**DHPLC for detection of homozygous sequence variants**

Analysis with DHPLC relies on heteroduplex detection and is therefore not suitable for detection of homozygous sequence variants unless mixed with a wild type sample in equal concentration. After this analysis all homozygous sequence variants were detected. After this analysis all homozygous sequence variants were detected. After this analysis all homozygous sequence variants were detected. After this analysis all homozygous sequence variants were detected. After this analysis all homozygous sequence variants were detected.

**DISCUSSION**

It was the aim of the current study to investigate the suitability of F-SSCP and DHPLC for mutation screening in the most common hereditary heart disease, HCM. The condition is caused by mutations in multiple disease genes and most families carry their own private mutation necessitating comprehensive genetic investigation of all protein encoding exons. The sensitivity and specificity of F-SSCP and DHPLC with respect to identification of sequence variants was compared with direct sequencing, which is often considered the “gold standard” for identification of unknown missense and small insertion or deletion mutations.

The sensitivity of F-SSCP and DHPLC was 95% and 100% respectively. However, there was no significant difference in detection rate between the two methods used (Fisher’s exact test, p=0.24). The high sensitivity of F-SSCP was achieved by labelling both forward and reverse primers with fluorescent dyes because 15% of all sequence variants were identified by the appearance of only one abnormal conformer of the amplified PCR product (fig 2). It was not apparent why sequence variants in some PCR products remained unidentified by F-SSCP analysis as they did not differ from PCR products with identifiable sequence variants with respect to GC content, length of the PCR product, or position of the sequence variation relative to the 5’ end of the PCR product.

The specificity of F-SSCP and DHPLC was 97% and 100% respectively. The PCR products identified by F-SSCP as false positive exhibited only minor variants from control samples. The appearance of false positive conformers in F-SSCP could be because of minor variants in electrophoresis conditions between capillaries, which might be induced by the presence of microscopic air bubbles or particles.

Both methods were highly reproducible but it was our experience that PCR products for DHPLC analysis should be stored at −20°C to obtain reproducible results, indicating that heteroduplexes in general were not stable at room temperature.

Before high throughput screening can be established PCR fragments for F-SSCP and DHPLC analysis need optimisation which is the time consuming part of both methods. However, in the current study PCR fragments on average only needed two different set of conditions for both methods before a suitable resolution for routine analysis was achieved. Once the
appropriate running conditions have been established the time burden of processing samples is limited because of the automation of both methods. The genetic analyser ABI 3100 has an overall capacity of analysing 576 (6 x 96) F-SSCP samples in 24 hours implying that 288 (3 x 96) samples can be processed at two different temperatures a day. Polymer needs to be added after analysis of 1344 (14 x 96) samples enabling continuous F-SSCP analysis for 56 hours without inspection of the machine. This is feasible because F-SSCP samples can be loaded automatically from two 384 well plates for repeated analysis at different temperatures. The 3500HT Wave genetic analyser has a capacity of 360 samples in 24 hours at one temperature and needs daily refilling of buffer reservoirs.

The fixed cost of buying a genetic analyser (ABI 3100) is about twice the price of a 350HT Wave genetic analyser. However, the 3500HT Wave genetic analyser requires additional equipment for subsequent direct sequencing of abnormal elution profiles. The cost of running the analysis of F-SSCP and DHPLC depends on the volume of samples processed. In our laboratory we aim at investigating 200 patients with HCM in nine recognised disease genes a year (about 136 PCR products for each patient) and in this setting the cost of both F-SSCP and DHPLC is less than 15% compared to direct sequencing. However, in a low throughput setting F-SSCP analysis is more expensive than DHPLC owing to the higher cost of primers labelled with fluorescent dyes.

In conclusion, F-SSCP and DHPLC analysis are valuable tools for high throughput mutation screening because both methods have high sensitivity and specificity when compared to identification of mutations by direct sequencing. In addition both methods require minimal “post-PCR” handling of samples, are easily optimised and have low running costs.

ACKNOWLEDGEMENTS
We thank Dr Juan Gimeno for statistical advice. The study was supported by grants from the British Heart Foundation, The Danish Medical Research Council, and The Danish Heart Foundation.

Authors’ affiliations
J Mogensen, A Bohi, T Kubo, N Elanko, R Taylor, W J McKenna, Department of Cardiological Sciences and Medical Genetics, St. George’s Hospital Medical School, London, UK, and the Department of Medicine and Geriatrics, Kochi Medical School, Kochi, Japan

Correspondence to: Dr J Mogensen, Department of Cardiological Sciences, St George’s Hospital Medical School, Cranmer Terrace, Tooting, SW17 0RE, London, UK; jmogensen@ghms.ac.uk

REFERENCES


www.jmedgenet.com
Comparison of fluorescent SSCP and denaturing HPLC analysis with direct sequencing for mutation screening in hypertrophic cardiomyopathy

J Mogensen, A Bahl, T Kubo, N Elanko, R Taylor and W J McKenna

J Med Genet 2003 40: e59
doi: 10.1136/jmg.40.5.e59

Updated information and services can be found at:
http://jmg.bmj.com/content/40/5/e59

These include:

References
This article cites 22 articles, 5 of which you can access for free at:
http://jmg.bmj.com/content/40/5/e59#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

- Cardiomyopathy (84)
- Epidemiology (630)
- Genetic screening / counselling (886)
- Molecular genetics (1254)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/